Company profile
SynAct Pharma company profile
SynAct Pharma AB develops drugs for acute deterioration in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriatic arthritis - a form of acute joint disorder that affects approximately 30 percent of patients suffering from psoriasis. Preclinical studies show that AP1189 has a unique ability to both reduce inflammation and accelerate bleeding, which is expected to reduce joint damage that may occur after acute inflammation of the joints of the joints. AP1189 has the potential to be given in tablet form once a day. Results from a clinical phase I study are expected..... For more information, log in to dureach.com to view the full company profile.
Business identity
- Contact email
- [email protected]
- Phone number
- +45 28 44 75 67
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00001-00010 employees
- Revenue range
- $1K+
- Founded
- 2012-01-01
Headquarters
- Headquarters
- Lund, Skane Lan, Sweden
- Postal code
- 223 81
- Country code
- SE
- Continent
- Europe